Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma - Wikidata - wikimedia - TriplyDB

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

http://www.wikidata.org/entity/Q33383268

about

mTOR inhibitors in advanced renal cell carcinoma The mTOR signalling pathway in human cancer Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities Combination therapy for renal cell cancer: what are possible options?Sunitinib in the treatment of metastatic renal cell carcinoma Approaches to modernize the combination drug development paradigm Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma.Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma.Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Molecular diagnosis and therapy of kidney cancer.Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.Efficacy and safety of everolimus in korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor.Renal cell carcinoma: molecular biology and targeted therapy Structure, development, preclinical and clinical efficacy of tivozanib (KRN-951, AV-951).Targeted therapies in the management of renal cell carcinoma: role of bevacizumab Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies.A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook.Experience with sunitinib in the treatment of metastatic renal cell carcinoma A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041).Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.Tivozanib in the treatment of renal cell carcinoma.Sunitinib for the management of advanced renal cell carcinoma.Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development.Sunitinib for metastatic renal cell carcinoma.Renal cell carcinoma: focus on safety and efficacy of temsirolimus.Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.Sorafenib for the management of advanced renal cell carcinoma.

P2860

Q24612127-8D1B5195-4204-4C5F-9DC7-9D42E163805D Q24627306-2BB7ADB9-6BD8-4549-B4B1-73195AEEDC52 Q26852437-0B71C3B9-6C16-4276-B79C-7B7C3F69DCA4 Q27011663-97C7B22D-0C0A-4103-87E9-584148EFE6FC Q28072057-630B6AFF-F0A1-4A41-9F2E-5BB4881518F3 Q28072074-2D1CECAA-D430-49A2-8B75-8AC3DC8CB1E7 Q30663984-4722534A-A218-4FD5-88DC-345D27D543B0 Q33397545-10CD1958-051D-4402-A322-F2A12C8FCE1E Q33408127-67884AD1-9AB8-47B7-A861-1041F5B86085 Q33419097-9E52054B-2BA6-4C6A-8B1B-CC481D6BB1AD Q33422258-D69964FB-CBB4-4B74-B777-1026D04F8E1F Q33424413-AA537B5C-4B00-4558-B571-8DF6443988E7 Q33985467-880AD650-608A-4296-9A3B-6D5B165E9089 Q34065685-16144740-96ED-4FC6-B447-B7AC0D65BC17 Q34129269-A8AB4E8B-2647-42FD-8B5B-D0FC68E8EDBB Q34363435-001D4394-3978-4921-B3BC-D5639C3F0CC0 Q34386054-D743D2C1-934C-4CCF-B645-AD700982D0FB Q34513914-3911FCF5-118E-416F-8572-A5EC03A8227B Q34517849-147C2109-F183-4BA2-ADDE-EA197F3BC161 Q34611205-1F8EAAFD-2294-45F0-BE2D-A99492DDE2BB Q34627828-ABA263BD-278B-4719-847F-97C66302C8E3 Q34629803-71E40477-1267-4D3A-95EE-4A7286E13361 Q34795914-314AAAA1-766D-4C2F-8C86-C7B9B72D2C21 Q35135727-EC2F7800-15E4-42B1-8B64-BBB4EF23A678 Q35504499-DCB4093D-135E-4BE0-9AEC-0F8E673F7A72 Q36040272-52454D39-CE06-4E53-96FD-71EC26AC1DCB Q36231729-8F429AFB-D768-4F59-8B71-96C08A56B6C4 Q36287414-2DD58372-E38C-4385-AEFF-3435EF3544AB Q36318627-283ED64E-30A9-4E5A-9BE4-DBB7C3F7C03F Q36480124-8B0A8BAB-C48B-4CD5-86BC-4ECA4EF341F3 Q36718942-2C8C21A0-92E5-404D-AA90-A8B63AE99EDC Q36818377-7E2EBA3A-6E98-4A0A-B805-8F24723F2CCE Q36933605-AA309B17-38BA-4FFF-9559-1A408D028A13 Q37705402-EA7E0328-D3B2-42D8-83B3-154F0E6CA57C Q37773367-0246AFC5-CDE8-471A-A956-7BFCC583B3E9 Q37797460-3CFD354A-CEA6-432F-A8F7-6E33E344C7F5 Q37828399-21D705E0-15FB-402D-89F8-BE566184C7F4 Q37838448-F266BA79-99C3-47B2-9C5D-7CDC9EB200C5 Q37866796-15AC4366-16CF-45A1-BABA-736D536D936C Q37894667-4BB60864-05BB-4051-A1AC-354F7C43F86D

P2860

Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma

http://www.wikidata.org/entity/Q33383268

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Phase I study combining treatm ...... advanced renal cell carcinoma

@ast

Phase I study combining treatm ...... advanced renal cell carcinoma

@en

type

label

Phase I study combining treatm ...... advanced renal cell carcinoma

@ast

Phase I study combining treatm ...... advanced renal cell carcinoma

@en

prefLabel

Phase I study combining treatm ...... advanced renal cell carcinoma

@ast

Phase I study combining treatm ...... advanced renal cell carcinoma

@en

P1433

Q33383268-5A16E772-4454-47E5-83A9-1F0A971FCE3C

P1476

Q33383268-AB2EA642-B326-4AF9-84B9-B5C8B15A51EA

P2093

Q33383268-0ABE5048-B2A6-47ED-9CF1-3D915DA5EC1B

Q33383268-AFB31C88-461D-4510-A849-39D9016B6622

Q33383268-BE47F977-C4C4-4031-B77E-D116FE287294

P2860

Q33383268-34E9F34C-2C22-4CAE-AF8B-EE17CBAED038

Q33383268-B761402E-9478-435F-9A43-16CB03A4599C

Q33383268-C4AA65AD-6A85-4F13-9B1E-F2B84730D469

Q33383268-D4DD4A44-0CF6-447C-91F9-DBDF05F71B7B

Q33383268-E2C075C2-F32A-48D8-859A-0F9795743D6B

Q33383268-E7B7165D-EC45-401F-A632-C3FDCDC54275

Q33383268-EBC58A0B-829E-4B39-912C-2032C74C9750

Q33383268-F8414B37-7D51-4EB4-8D98-02B23B0FB0F6

Q33383268-FB183D7C-7C24-4C6B-81E4-F4CE4CFFB3E4

Q33383268-FED27F9A-081B-4A03-80FF-67DC022754F9

P304

Q33383268-ABE82359-FBF7-4E5B-B96D-D25E3C8D1D59

P31

Q33383268-C422080D-5651-4E84-ADC3-3E88CEE688D3

P356

Q33383268-15E2D934-BF62-4CE2-8915-78A7E1ED75D1

P407

Q33383268-2C798354-9368-49C8-9D9F-BE6DF5AB4C17

P433

Q33383268-0A7C815C-FAC3-40F5-AE75-A148756BC8C9

P478

Q33383268-1153A8F0-0C1D-409E-A35C-69C0FDEB400F

P50

Q33383268-F0FC834B-582A-40AF-8D76-B1C09075A29C

P577

Q33383268-164CD5BF-6A7D-49B8-849F-981E2E10C3C8

P698

Q33383268-02E263F0-429F-43E7-B3C3-618A6FF67571

P932

Q33383268-35BB6BE2-2B86-4436-B3EF-C39752E660A8

P356

P1433

Clinical Genitourinary Cancer

P1476

Phase I study combining treatm ...... advanced renal cell carcinoma

@en

P2093

Peggy L Senico

http://www.w3.org/2001/XMLSchema#string

Premal H Patel

http://www.w3.org/2001/XMLSchema#string

Rafael E Curiel

http://www.w3.org/2001/XMLSchema#string

P2860

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

Defining the role of mTOR in cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

Targeting von Hippel-Lindau pathway in renal cell carcinoma.

Opportunities and obstacles to combination targeted therapy in renal cell cancer.

Sunitinib: from rational design to clinical efficacy.

The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy.

Targeted drugs for metastatic renal cell carcinoma.

P304

24-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3816/CGC.2009.N.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19213664

http://www.w3.org/2001/XMLSchema#string

P932

3740755

http://www.w3.org/2001/XMLSchema#string